Tufts University School of Medicine's Yongjie Yang, published a study in the Journal of Neuroscience that recognizes an astroglial trigger mechanism as supplying to symptoms of fragile X syndrome in mice.

Fragile X syndrome (FXS) is an inherited condition, in which the distinctive nature is described by an X chromosome that is abnormally susceptible to damage, into a great extent by folic acid deficiency. Individuals who are affected by fragile X syndrome (FXS) tend to be mentally handicapped.

The FXS is the most common starting point of inherited intellectual disability in humans and this genetic condition is connected with autism spectrum disorder, based on the report of Tufts Now.

Astroglia, that helps pattern the brain in fetal development, are abundant in the brain and help control neuronal signaling. Astroglia are necessary part  in a number of neurological disorders, which includes FXS, but a research needs to be done about how they become dysfunctional and contribute to disease.

As the researchers used genetically engineered mice, Yang and his team selectively put a stop to astroglia from producing FMRP. The researchers observed that the animals developed symptoms are comparable to those seen in fragile X syndrome. The researchers recognized an astrocyte-specific glutamate transporter (GLT1), in which, when drastically altered, it led to an imbalance of glutamate signaling.

On the other hand, the president of the American Academy of Pain Medicine and director of pain research at Tufts University School of Medicine in Boston - Dr. Daniel Carr, stated that by altering the mood of a person, Marijuana could help treat pain  as well as it can treat depression and anxiety.

Carr also said that from the patient's point of view, the effects of Marijuana on people's mood could also alleviate the experience of pain. However, more research needs to be done on Marijuana in order for it to serve as a replacement to prescription drugs, according to UPI.